Your Cheat Sheet For Q1 Biotech Earnings

Previewing first-quarter results of biotech companies, Jefferies said it sees some modest misses across the board, going by its deduction that the first quarter tends to be soft and its Rx analysis. However, the firm said this perspective would not dampen its enthusiasm, given a recent string of positive data points/product approvals.

Signs Of Encouragement Seen

Analyst Brian Abrahams sees continued signs of encouragement for the sector as 2017 progresses, based on a few premises. Given the leadership groundwork set for an FDA that is workable and industry-friendly, the analyst believes any drastic healthcare reform measures in 2017 will be delayed, if not altogether off the table near term.

Positive Investor Sentiment

Additionally, Jeffries gets winds of the biotech stock performance building on its early momentum, based on its recent investor survey. The firm noted the 10 percent, plus, gains of the iShares NASDAQ Biotechnology Index (ETF) IBB. The firm expects the positivity to be propelled by increasing M&A activity. However, the firm cautioned of long-term competitive/pricing pressures.

Q1 Statistics

Highlighting key first-quarter statistics, the firm noted that the quarter had 62 selling days versus 63 days in fourth quarter of 2016. The quarter saw modest dollar strength. Among the potential beats are Gilead Sciences, Inc. GILD's Odefsey, Descovy and Epclusa, while Gilead Sciences' Truvada, Atripala and Complera Biogen Inc BIIB's Plegridy are among the potential misses.

Peek Into Individual Biotech Stocks (Earnings Date/Rating/Price Target

  • Bioverativ Inc. BIVV: Buy.
  • Biogen: April 25, 2017, 8:30 a.m. ET/Hold/Lowered to $281.
  • Amgen, Inc. AMGN: April 26, 2017, 5 p.m. ET/Hold.
  • Alexion Pharmaceuticals, Inc. ALXN: April 27, 2017 (projected)/Hold.
  • BioMarin Pharmaceutical Inc. BMRN: April 27, 2017 (projected)/Buy.
  • Celgene Corporation CELG: April 27, 2017, 9 a.m. ET/Buy/$154.
  • United Therapeutics Corporation UTHR: April 27, 2017 (projected)/Underperform.
  • Swedish Orphan Biovitrum AB (SOBI.ST): April 28, 2017/Buy.
  • AMAG Pharmaceuticals, Inc. AMAG: May 2, 2017 (projected)/Buy.
  • Gilead Sciences: May 2, 2017, 4:30 p.m. ET/Buy/Lowered to $82.
  • Vertex Pharmaceuticals Incorporated VRTX: May 3, 2017 (projected)/Buy/$126.
  • Alkermes Plc ALKS: May 4, 2017 (projected)/Buy.
  • Incyte Corporation INCY: May 4, 2017 (projected)/Buy/Upped to $165.
  • Spectrum Pharmaceuticals, Inc. SPPI: May 4, 2017, 4:30 p.m. ET/Buy/Raised to $8.50.
  • Vanda Pharmaceuticals Inc. VNDA: May 4, 2017, 4:30 p.m. ET/Buy/$21.
  • Regeneron Pharmaceuticals Inc REGN: May 5, 2017 (projected)/Hold.
  • Heron Therapeutics Inc HRTX: May 11, 2017 (projected)/Buy.
Related Links:

13 Emerging Biotechs With Catalysts In 2017 Oppenheimer Bullish On Entire Biotech Sector Icahn's (Potential) Move Into Biotech

Posted In: AtripalaBrian AbrahamsCompleraDescovyEpclusaJefferiesOdefseyPlegridyTruvadaAnalyst ColorBiotechEarningsLong IdeasNewsGuidanceHealth CarePreviewsAnalyst RatingsMoversTrading IdeasGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.